Emerging Biotech · mAb, ADC, recombinant
The Future of Biopharma
The Chemical Engineering magazine has published its third article of the biopharmaceutical manufacturing series, written by David Gemmell….
David Gemmell
David Gemmell has been working for
Merck KGaA, Darmstadt, Germany
MilliporeSigma
for over six years. David is currently employed with the Technical & Scientific Solutions MSAT (Manufacturing Sciences & Technology) department. David’s primary focus is on optimising or troubleshooting downstream purification unit operations for customers, focusing on both novel and traditional modalities, across all purification technologies. He is also the High Temperature Short Time Subject Matter Expert for upstream viral risk mitigation. At University David obtained a BEng (Hons) in Chemical Engineering and an MSc in Advanced Chemical & Process Engineering. His early career was based in the nuclear and power generation sectors before moving into biopharmaceutical and life sciences.
Emerging Biotech · mRNA
Biopharmaceutical Manufacturing: An Evolving Industry
Chemical Engineering Magazine has published its second article of the biopharmaceutical manufacturing series, written by Biomanufacturing Engineer, David…
